Prostate cancer is the most frequently diagnosed male cancer and second leading cause of male cancer death. If primary treatment modalities are not capable of controlling the disease, inhibiting androgen receptor (AR) activity is an effective treatment for advanced prostate cancer patients. However, the duration of patient responses to AR-targeted therapy is variable, and all patients will ultimately develop resistance and progress to a castration-resistant form of the disease associated with morbidity and death. One important feature of castration-resistant prostate cancer (CRPC) is aberrant re-activation of AR transcriptional activity despite reduced levels of circulating androgens. This knowledge has led to the development of new therapies that inhibit mechanisms supporting residual transcriptional activity of the AR in CRPC. However, resistance remains a major limitation for these new AR-targeted agents. Because of the major need for new understanding and innovation in this area, the long-term objectives of this research are to determine the mechanisms that can support persistent AR transcriptional activity despite AR-targeted therapy, and to develop more effective strategies for treating and managing patients with CRPC. The central discovery driving the proposed studies is altered AR mRNA splicing, giving rise to COOH-terminally truncated AR variant (AR-V) proteins that achieve constitutive transcriptional activity in the complete absence of androgen stimulus. Synthesis of these AR-Vs has emerged as an important aspect of clinical CRPC progression, but mechanisms responsible for alterations in AR splicing are largely unknown. The overarching goal of this proposal is to understand the role of newly-discovered AR gene rearrangements in driving altered AR splicing patterns and efficient AR-V synthesis in CRPC. To achieve this goal, three specific aims are proposed.
In Aim 1, an arsenal of customized next-generation DNA and RNA sequencing tools will be used to determine the spectrum of AR gene rearrangements and splicing alterations in tissues from patients with CRPC.
In Aim 2, programmable nuclease technology will be used to experimentally engineer site-specific AR gene rearrangements in the prostate cancer genome. These genome-engineered cells will be studied to establish the links between architectural changes in the AR gene, aberrant AR mRNA splicing patterns, AR-V synthesis, and the CRPC phenotype.
In Aim 3, AR gene rearrangements will be evaluated as new biomarkers for detecting AR-V driven CRPC cell populations in heterogeneous tumors, predicting responses to AR-targeted therapy, and monitoring the development of resistance during AR-targeted therapy. Success with these studies will establish the role of an entirely new class of AR gene alterations in prostate cancer progression, and provide new methods for evaluating AR gene status in prostate cancer cells. Knowledge and resources developed in this proposal will be important for developing new treatment regimens for prostate cancer based on an individual patient's unique AR gene architecture.

Public Health Relevance

Inhibiting activity of the androgen receptor (AR) in advanced prostate cancer is initially an effective therapy, yet development of resistance ultimately leads t unchecked growth of metastatic disease, morbidity, and death. This proposal seeks to understand the significance of a new alteration in the prostate cancer genome that may underlie the development of resistance to AR-targeted therapy. This knowledge could lead to the design of more effective strategies to inhibit AR activity and better management of patients with advanced prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA174777-02
Application #
8625287
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Sathyamoorthy, Neeraja
Project Start
2013-04-01
Project End
2018-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
2
Fiscal Year
2014
Total Cost
$305,177
Indirect Cost
$101,245
Name
University of Minnesota Twin Cities
Department
Pathology
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Kohli, Manish; Ho, Yeung; Hillman, David W et al. (2017) Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. Clin Cancer Res 23:4704-4715
Ho, Yeung; Dehm, Scott M (2017) Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer. Endocrinology 158:1533-1542
Daniel, Mark; Dehm, Scott M (2017) Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer. J Steroid Biochem Mol Biol 166:28-37
Van Etten, Jamie L; Nyquist, Michael; Li, Yingming et al. (2017) Targeting a Single Alternative Polyadenylation Site Coordinately Blocks Expression of Androgen Receptor mRNA Splice Variants in Prostate Cancer. Cancer Res 77:5228-5235
Van Etten, Jamie L; Nyquist, Michael; Li, Yingming et al. (2017) Targeting a single alternative polyadenylation site coordinately blocks expression of androgen receptor mRNA splice variants in prostate cancer. Cancer Res :
Dalal, Kush; Che, Meixia; Que, Nanette S et al. (2017) Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions. Mol Cancer Ther 16:2281-2291
Yin, Yi; Li, Rui; Xu, Kangling et al. (2017) Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation. Cancer Res 77:4745-4754
Paltoglou, Steve; Das, Rajdeep; Townley, Scott L et al. (2017) Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer. Cancer Res 77:3417-3430
Henzler, Christine; Li, Yingming; Yang, Rendong et al. (2016) Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. Nat Commun 7:13668
Asim, Mohammad; Massie, Charles E; Orafidiya, Folake et al. (2016) Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. J Natl Cancer Inst 108:

Showing the most recent 10 out of 28 publications